

APME



**TOP 20 HEALTH CARE
COMPANIES**

2023



Petr Svoreň

CEO

APME FX TRADING EUROPE LTD

Dear friends and colleagues,
The coronavirus pandemic has turned almost everyone's life upside down. It has had far-reaching effects on society, including its habits, the way it behaves or takes care of its health. It significantly affected the economy of each affected country and created several winners and losers. With the gradual end of the pandemic, not only ordinary life, but also the healthcare sector is returning to normal. Some companies in the industry have been able to use the experience of covid and transform it into their future, others have not. Two years since our first study on business of pharma & health care industries, we are bringing you our annual investment update.

The coronavirus crisis had a significant impact on the finances of virtually all pharmaceutical companies that were somehow involved in the development of vaccines against the coronavirus or drugs for the disease covid-19. At first, they experienced a huge increase in sales and profit, after the pandemic subsided, on the contrary, we have been witnessing a sharp decline.

However, this does not apply in all cases. Those companies that did not rely too much on covid were able to withstand the end of the pandemic. These are mainly pharmaceutical giants such as Pfizer, Johnson & Johnson or AstraZeneca, whose business with vaccines or anti-covid drugs is not standing or falling.

But the healthcare sector has also seen several cases where companies are fighting for their existence. This is especially the case with companies such as BioNTech, Moderna or Novavax. They bet too much on vaccines and if they fail to use the experience gained, their life cycle will most likely close.

However, it was not only the coronavirus crisis that significantly affected the healthcare sector. Practically immediately, it was replaced by an inflationary crisis, which represents a significant burden for the health systems of individual countries. Here, too, it is partly a consequence of covid, which has disrupted supply chains and exposed the healthcare systems to another difficult test: the lack of medicines.

Most active substances are produced in China or India, so Europe or the United States must face problems with the supply of medicinal products. However, this has the effect of increasing pressure on public health insurance budgets when drug manufacturers deliver their products primarily where they can be paid decently for them.

Related to this is the threat of pharmaceutical companies leaving countries where governments intend to save money at all costs. We could witness something like this at the turn of 2022 and 2023 in Great Britain, from where the American companies Eli Lilly and AbbVie are moving. And they are looking for a more attractive environment

How the major world's players that are listed are doing please see in our chart and corporate profiles bellow.

Have an inspiring reading!

TOP 20 HEALTH CARE COMPANIES	MARKET CAP*
UnitedHealth Group Inc.	451.37
Eli Lilly	415.28
Johnson&Johnson	413.22
Merck & Co.	291.2
Novo Nordisk	286.84
AstraZeneca	228.79
Pfizer	208.2
Sanofi	135.11
Medtronic	117.85
Anthem Inc.	105.7
Gilead Sciences	98.22
Regeneron	82.14
Boston Scientific	76.79
GlaxoSmithKline	73.73
Humana Inc.	65.01
Bayer AG	57.18
Moderna	47.19
Biogen	44.36
Centene Corp	36.88
BioNTech	26

EXCHANGE RATES

1,08 USD/EUR

1,25 USD/GBP

0,15 USD/DKK*

* As at 16 May 2023



UnitedHealth Group[®]

UNITEDHEALTH GROUP INC.

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	451.37	+5.72
Market cap. (as of 3.1.2022)	426.97	
Revenues 2022	324.20	+12.73
Revenues 2021	287.60	
Net income 2022	4.91	+17.18
Net income 2021	4.19	

SOURCE: Annual report, NYSE*

UnitedHealth Group Inc. is America's largest health insurance company. Both in terms of the amount of market capitalization, sales or profit, and the number of insured persons. UnitedHealth has 70 million of them in its portfolio. At the same time, it cooperates with 1.3 million doctors and around 6.5 thousand hospitals. In addition to the United States, it also operates in Latin America. Health insurance company UnitedHealth was founded in 1977 and its portfolio includes several smaller insurance companies and employs more than 125,000 people.



ELI LILLY

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	415.28	+68.58
Market cap. (as of 3.1.2022)	246.34	
Revenues 2022	28.54	+0.78
Revenues 2021	28.32	
Net income 2022	6.24	+11.83
Net income 2021	5.58	

SOURCE: Annual report, NYSE*

The American pharmaceutical company Eli Lilly was founded in 1876. It became famous, for example, as the first serial producer of the polio vaccine or insulin. Today, Eli Lilly is the largest producer of psychiatric drugs such as Prozac, Dolophine or Zyprexa. In connection with the coronavirus, Eli Lilly came to public attention thanks to the drug Bamlanivimab, which is used as an experimental treatment for covid-19. The end of the covid pandemic did not have a negative impact on Eli Lilly's finances, the company has higher sales and net profit than before the pandemic. Only the first quarter of this year shows that they must expect a decrease in sales and profit. [1]


Johnson & Johnson

JOHNSON & JOHNSON

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	413.22	-8.65
Market cap. (as of 3.1.2022)	452.35	
Revenues 2022	94.94	+1.24
Revenues 2021	93.78	
Net income 2022	17.94	-14.08
Net income 2021	20.88	

SOURCE: Annual report, NYSE*

Johnson & Johnson is the world's largest pharmaceutical company by market capitalization. In its portfolio we can find a wide range of products from the field of healthcare and pharmacy, including consumer pharmacy, hygiene or medical devices, aids, and materials. The history of the company dates back to 1886. Its group includes several companies, including the biotechnology company Janssen, which developed an effective vaccine against the coronavirus. However, it is not a core product, so Johnson & Johnson is a stable company regardless of the course of the pandemic. In the first quarter of this year, the company's sales rose 5.6 percent, but Johnson & Johnson posted a loss of \$68 million. This was the result of a fine the company had to pay due to earlier disputes over the harmfulness of some of its childcare products.



MERCK

MERCK & CO.

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	291.20	+42.91
Market cap. (as of 3.1.2022)	203.76	
Revenues 2022	59.28	+21.72
Revenues 2021	48.70	
Net income 2022	14.52	+17.57
Net income 2021	12.35	

SOURCE: Annual report, NYSE*

The American pharmaceutical company Merck was founded in 1891 as a branch of the German company Merck, whose history dates back to the last third of the 17th century. The company develops drugs, vaccines, and also biological therapies. Among its best-known products are, for example, the immunotherapy drug for the treatment of cancer Keytruda, the HPV vaccine Gardasil, or the pneumococcal vaccine Pneumovax 23. In total, it has several products, each of which brings the company about a billion dollars in annual turnover. However, the first three months of this year for Merck meant a year-on-year decrease in sales by nine percent, and net profit fell by more than a third.



NOVO NORDISK

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	286.84	+64.65
Market cap. (as of 3.1.2022)	174.21	
Revenues 2022	25.75	+25.67
Revenues 2021	20.49	
Net income 2022	8.08	+16.26
Net income 2021	6.95	

SOURCE: Annual report, NYSE*

The Danish multinational pharmaceutical company Novo Nordisk is a global leader in the field of diabetes treatment. It has almost a hundred years of tradition, it was founded at the end of 1923. In addition to diabetes, it focuses on the development and production of medicinal products for patients with haemophilia, or for the treatment of growth hormone problems and hormone replacement therapy. Two years ago, Novo Nordisk entered into a partnership with the American biopharmaceutical company Lumen Bioscience, within the framework of which it will develop a therapy for the treatment of obesity and metabolic disorders. In the first three months of this year, Novo Nordisk increased sales by 27 % year-on-year, and net profit by even 39 %.

AstraZeneca

ASTRAZENECA

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	228.79	+41.47
Market cap. (as of 3.1.2022)	161.72	
Revenues 2022	42.99	+14.89
Revenues 2021	37.42	
Net income 2022	3.29	+2641.67
Net income 2021	0.12	

SOURCE: Annual report, NYSE*

The British-Swedish pharmaceutical group was founded in 1992. It focuses on a wide range of medicinal products, especially for the treatment of cancer, infections, neurological, cardiovascular, or gastrointestinal diseases. It is among the first companies to receive the green light from regulators for the application of a vaccine against SARS-CoV-2, which it has already developed in collaboration with the University of Oxford. However, the initial success was replaced by doubts about the safety of the vaccine. However, the strength of the group is that its stability is not linked to the coronavirus vaccine. AstraZeneca's sales in the first quarter of this year fell by only four percent year-on-year, after deducting the effect of vaccines against the coronavirus, on the contrary, they showed a 10 percent increase. For this year, the group expects sales growth of 15 percent, if we exclude the effect of covid-related drugs.



PFIZER

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	208.20	-33.85
Market cap. (as of 3.1.2022)	314.74	
Revenues 2022	100.33	+23.42
Revenues 2021	81.29	
Net income 2022	31.37	+42.72
Net income 2021	21.98	

SOURCE: Annual report, NYSE*

The American group Pfizer, whose history dates to 1849, is among the ten largest pharmaceutical companies in the world by market capitalization. With its business, it covers a whole range of medicinal products or vaccines. It develops and supplies drugs for treatment in the fields of oncology, cardiology, immunology, or neurology. The Pfizer company came to the attention of the wider public mainly thanks to its leadership in the development of a vaccine against the coronavirus, which was approved by both the American and European regulators for application before the end of 2020. Sales of the vaccine under the trade name grew so much that the total sales of the Pfizer group rose in in 2022 compared to 2020 to 2.5 times. Its net profit showed similar dynamics. For this year, however, the group expects a gradual return to normal because of the end of the covid pandemic and a decrease in demand for both the vaccine and the drug Paxlovid, which is administered to covid patients. Pfizer estimates its sales in the range of 67 to 71 billion dollars for 2023. [2]


 The Sanofi logo is displayed in a large, bold, black sans-serif font. The letters 's' and 'i' are lowercase, while 'anofi' are uppercase. Two small purple circles are positioned above the 'i' and below the 's'.

SANOFI

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	135.11	+12.19
Market cap. (as of 3.1.2022)	120.43	
Revenues 2022	46.50	+13.89
Revenues 2021	40.83	
Net income 2022	7.27	+8.02
Net income 2021	6.73	

SOURCE: Annual report, NYSE*

The French pharmaceutical group Sanofi was established in 2004 by gradually merging companies at the international level. Today it is a global and highly diversified company. It develops, manufactures, and supplies medicines, vaccines, but also innovative therapeutic solutions. An important part of the group is its own research and development in the treatment of multiple sclerosis, diabetes, oncological and rare diseases, cardiovascular and metabolic diseases or immunology. It is a global market leader in vaccines and veterinary care. In the first quarter of this year, Sanofi increased sales by 5.7 percent year-on-year, while net profit fell only slightly, by 0.7 percent.

Medtronic

MEDTRONIC

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	117.85	-15.77
Market cap. (as of 3.1.2022)	139.91	
Revenues 2022	31.69	+5.21
Revenues 2021	30.12	
Net income 2022	5.04	+39.61
Net income 2021	3.61	

SOURCE: Annual report, NYSE*

Medtronic is one of the world's leading manufacturers of medical devices, and equipment. Founded in 1949 in Minneapolis, it introduced the first battery-powered wearable pacemaker eight years later. In the following years, the company focused on the field of cardiology, later neurology, spinal surgery, or diabetes. Two years ago, she developed a system for robot-assisted spine surgery. Today, Medtronic is based in Ireland, but has its operational headquarters in Minnesota, USA. The first months of this year brought year-on-year practically constant sales with a slight decrease in profit by four percent.



Elevance Health

ELEVANCE HEALTH (ANTHEM INC.)

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	105.70	+5.69
Market cap. (as of 3.1.2022)	100.01	
Revenues 2022	133.23	+13.51
Revenues 2021	117.37	
Net income 2022	6.02	+0.17
Net income 2021	6.01	

SOURCE: Annual report, NYSE*

Anthem Inc. is the second largest American health insurance company. It provides financing for health care for approximately 40 million insured persons. It was created in 2004 because of a merger with WellPoint and until 2014 it bore this name. Over the past 17 years, the insurance company Anthem has acquired several smaller health insurance companies in its portfolio, and thus managed to expand the number of insured. Over the last ten years, it has managed to double its sales and increase its net profit by almost three quarters. The company's market value has grown roughly sixfold over the same period. During 2022, Anthem Inc. was renamed to Elevance Health Inc.



GILEAD

GILEAD SCIENCES

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	98.22	+10.67
Market cap. (as of 3.1.2022)	88.75	
Revenues 2022	27.28	-0.11
Revenues 2021	27.31	
Net income 2022	4.57	-26.29
Net income 2021	6.20	

SOURCE: Annual report, NYSE*

The American pharmaceutical company Gilead Sciences focuses mainly on the development of antiviral drugs. It was founded in 1987. Among its best-known products is Tamiflu, which is used to treat the flu. But also, Viread, used in the treatment of HIV/AIDS and hepatitis B. Gilead Sciences bought the patent for this substance from the Czech biochemist Antonín Holé and his team. Gilead also developed the experimental drug remdesivir, which shows effects against diseases caused by the Ebola and Marburg viruses, but also RNA viruses, including coronaviruses. Gilead is also among the pharmaceutical companies that manage to keep their sales at a solid level even after the end of the covid pandemic. In this year's first quarter, they fell only slightly year-on-year (by less than 4 percent), while net profit increased more than 80 times.

REGENERON

science to medicine®

REGENERON

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	82.14	+24.02
Market cap. (as of 3.1.2022)	66.23	
Revenues 2022	12.17	-24.27
Revenues 2021	16.07	
Net income 2022	4.34	-46.29
Net income 2021	8.08	

SOURCE: Annual report, NYSE*

The American biotechnology company Regeneron was founded in 1988 and originally focused on the research and production of neurotrophic factors and their regenerative abilities. These are proteins that stimulate the growth of brain cells. Regeneron also used its experience in the development of a drug based on the proteins casirivimab and imdevimab, which are supposed to prevent the virus from entering human cells. The drug is used to treat covid-positive patients who have not developed enough antibodies. In the case of Regeneron, too, the recession of the pandemic had a certain effect on its financial results. In this year's first quarter, however, the company increased sales by two percent year-on-year and slightly improved its full-year outlook.

Boston Scientific

BOSTON SCIENTIFIC

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	76.79	+26.83
Market cap. (as of 3.1.2022)	60.55	
Revenues 2022	12.68	+6.64
Revenues 2021	11.89	
Net income 2022	0.698	-32.88
Net income 2021	1.04	

SOURCE: Annual report, NYSE*

The American company Boston Scientific is also one of the world's leading manufacturers of medical devices and aids. It was founded in 1979 as a Medi-Tech company and its spiritual father was a Palestinian emigrant of Czech origin, Itzak Bentov. In 1992, Boston Scientific went public and expanded its scope through several acquisitions. Today, it supplies its products to several interventional medical fields, including interventional radiology, interventional cardiology, neuromodulation, neurovascular intervention, electrophysiology or cardiac and vascular surgery. The company is known, for example, for developing a stent, which is used to open arteries, or an implantable cardioverter-defibrillator. In the first quarter of this year, the company reported year-on-year sales growth of 12 percent and managed to almost triple its net profit.



GLAXOSMITHKLINE

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	73.73	-10.73
Market cap. (as of 3.1.2022)	82.59	
Revenues 2022	36.63	+18.70
Revenues 2021	30.86	
Net income 2022	6.15	+39.77
Net income 2021	4.40	

SOURCE: Annual report, NYSE*

The British multinational pharmaceutical group was formed in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham. GSK is one of the leading companies in the consumer pharmaceutical business. But its portfolio also includes standard medicines, vaccines or medicines for asthma, oncological diseases, diabetes, infectious and inflammatory diseases or for the treatment of mental disorders. Emma Walmsley has been the head of the company since April 2017. Although GSK reported a year-on-year decrease in sales in the first quarter of this year, sales rose by more than ten percent without the effect of covid medicines.

Humana

HUMANA INC.

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	65.01	+43.26
Market cap. (as of 3.1.2022)	45.38	
Revenues 2022	92.87	+11.81
Revenues 2021	83.06	
Net income 2022	3.57	+6.57
Net income 2021	3.35	

SOURCE: Annual report, NYSE*

Humana Inc. is one of America's oldest health insurance companies. It was established in 1961 and belongs to medium-sized enterprises in the sector. It manages health insurance for almost 17 million clients. Humana was supposed to become part of rival insurance company Aetna in 2015, when it was about to be acquired for \$37 billion. But in the end, the American judiciary prevented the deal, saying that competition in the American health insurance market would be threatened. By the end of 2022, Humana had almost 49,000 employees.



BAYER AG

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	57.18	+10.25
Market cap. (as of 3.1.2022)	51.86	
Revenues 2022	54.87	+15.10
Revenues 2021	47.67	
Net income 2022	4.49	+315.74
Net income 2021	1.08	

SOURCE: Annual report, NYSE*

Bayer AG is a German agrochemical and pharmaceutical group. It was founded in 1863 and today it includes over 300 companies. Among them is the American agricultural and agrochemical company Monsanto, which Bayer bought for 63 billion dollars almost five years ago. At the time, it was the largest acquisition ever undertaken by a German company. Currently, he is also focusing on innovative cell and gene therapy, which he is trying to apply in the treatment of Parkinson's disease. In the first quarter of 2023, Bayer's sales fell by 1.7 and net profit by about 33 percent year-on-year.

moderna®

MODERNA

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	47.19	-26.83
Market cap. (as of 3.1.2022)	64.47	
Revenues 2022	19.26	+4.28
Revenues 2021	18.47	
Net income 2022	8.36	-31.48
Net income 2021	12.20	

SOURCE: Annual report, NYSE*

The American biotechnology company Moderna also wrote its success story only thanks to the coronavirus pandemic. It was established in 2010 and shortly after that it entered cooperation with the British-Swedish group AstraZeneca. She focused her research and development on innovative drugs based on mRNA technology, i.e., inducing an immune response in cells, thanks to which the organism should then be able to effectively defend itself against a wide range of diseases. Moderna saw its rise during 2020 when it developed an effective vaccine against the coronavirus. Although the covid crisis has passed, Moderna benefits from the experience gained and develops vaccines against other infections for which it uses mRNA technology. These are, for example, flu vaccines. In the first quarter of this year, Moderna recorded a year-on-year drop in sales by about two-thirds, net profit fell by 98 percent to almost \$80 million.



Biogen

BIOGEN

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	44.36	+31.76
Market cap. (as of 3.1.2022)	33.67	
Revenues 2022	10.17	-7.38
Revenues 2021	10.98	
Net income 2022	2.96	+71.10
Net income 2021	1.73	

SOURCE: Annual report, NYSE*

The American biotechnology company Biogen has its origins in Switzerland. It was founded in 1978 in Geneva by leading biologists, two of whom later won the Nobel Prize. Through a merger with the California company IDEC Pharmaceuticals, it reached American soil. She focused her research on finding a cure for cancer. Thanks to subsequent acquisitions, it expanded the portfolio of medicinal products and penetrated neurology. It supplies the market with the drug Leqembi, which slows the progression of Alzheimer's disease. That's also why Biogen's stock has gained more than 50 percent in value over the past year. Biogen also did relatively well in the first quarter of this year, when it kept its sales at almost the same level as last year. Net profit even rose slightly.

CENTENE® Corporation

CENTENE CORP.

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	36.88	-11.97
Market cap. (as of 3.1.2022)	41.90	
Revenues 2022	144.55	+14.74
Revenues 2021	125.98	
Net income 2022	3.36	+10.53
Net income 2021	3.04	

SOURCE: Annual report, NYSE*

American health insurer Centene Corp. belongs to medium-sized companies within its field. In addition to health insurance, it also offers regular insurance products. It provides its services to approximately 25 million policyholders in all US states. But it is also present in the health insurance market in Europe, through its partnerships in Slovakia, Spain, and Great Britain. The insurance company was founded in 1984 and employs around 70,000 people.

BIONTECH

BIONTECH

INDICATOR	BN USD	Y-O-Y CHANGE IN %
Market cap. (as of 16.5.2023)	26.00	-49.09
Market cap. (as of 3.1.2022)	51.07	
Revenues 2022	18.72	-8.82
Revenues 2021	20.53	
Net income 2022	10.20	-8.36
Net income 2021	11.13	

SOURCE: Annual report, NYSE*

This German biotechnology company was founded only in 2008. From the beginning of its existence, it focused on the development of technologies based on biological treatment, i.e., inducing a specific immune response of the organism using proteins and mRNA. And primarily in the field of oncological diseases. The goal was for the body to deal with the tumor with the help of its own cells. However, BioNTech also achieved success in connection with the coronavirus pandemic, when it developed the vaccine Comirnaty against SARS-CoV-2 in cooperation with the Pfizer group. And like Pfizer, BioNTech's sales and profits grew rapidly thanks to Comirnaty, but are now starting to decline. In the first quarter of this year, there was a year-on-year drop in sales of 80 percent. The company's net profit fell even by 86 percent. For this year as a whole, BioNTech expects sales of around five billion dollars. [3]

* Past performance is no guarantee of future results.

[1,2,3] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or based on the current economic environment which is subject to change. Such statements are not guaranteeing of future performance. They involve risks and other uncertainties which are difficult to predict. Results could differ materially from those expressed or implied in any forward-looking statements.



Want to know more?

Do not hesitate to get in touch with committed professionals of APME FX:

Head Offices Number:

+357 25 054 734

info@apmefx.com

www.apmefx.com

APME FX TRADING EUROPE LTD

Spyrou Kyprianou 25
Floor 1/Office 103
3070, Limassol
Cyprus

APME



World Health Care Investments 2023 is an informative, educational, and marketing publication and does not represent any investment recommendation.

Information of the previous performance of a financial instrument does not guarantee its current and/or future performance. The use of historical data does not constitute a binding or safe forecast as to the corresponding future performance of the financial instruments to which the said information refers.

APME FX TRADING EUROPE LTD is a Cyprus Investment Firm (CIF) supervised and regulated by the Cyprus Securities and Exchange Commission (CySEC) with a CIF licence number 335/17.

APME FX TRADING EUROPE LTD provides trading opportunities in the dynamic environment of Forex market. Forex is the market where the world's currencies trade and the most liquid market in the world. Currencies are not traded in a regulated market or exchange but over the counter (OTC) instead.

Forex trading allows to buy and sell currencies, like stock trading except you can do it 24 hours a day, five days a week, you have access to margin trading, and you gain exposure to international markets. Trading foreign exchange on margin carries a high level of risk and may not be suitable for everyone. Before deciding to trade foreign exchange, you should carefully consider your investment objectives, level of experience, and risk appetite. Remember, you could sustain a loss of some or all your initial investment, which means that you should not invest money that you cannot afford to lose. If you have any doubts, it is advisable to seek advice from an independent financial advisor.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 83.64% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.